FindTrial
Sign In

Psilocybin (drug)

DRUG12 trials

Sponsors

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Claudio N Soares, Yale University, Beersheva Mental Health Center, M.D. Anderson Cancer Center

Conditions

Anhedonia in Healthy VolunteersAnxietyCognitive Behavioral TherapyDepressionDepression - Major Depressive DisorderGeneralized Anxiety Disorder (GAD)Healthy ParticipantsMajor Depression

Early Phase 1

Psilocybin as a Treatment for Chronic Pain in Smokers
RecruitingNCT07118332
Yale UniversitySmokers With Chronic Pain
Start: 2026-07-06End: 2027-12-01Target: 10Updated: 2026-08-03
Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD
RecruitingNCT07737054
Tel-Aviv Sourasky Medical CenterPost-Traumatic Stress Disorder, PTSD
Start: 2025-07-22End: 2026-12-31Target: 13Updated: 2026-07-30

Phase 1

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
CompletedNCT00302744
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterAnxiety
Start: 2004-04-30End: 2008-12-31Updated: 2025-03-13
RCT of Psilocybin-assisted CBT for Depression
RecruitingNCT07281352
University of California, Los AngelesMajor Depressive Diorder
Start: 2026-01-05End: 2027-11-30Target: 50Updated: 2026-02-12
A Study of Psychedelics in Healthy Older Adults With Low Well-being
RecruitingNCT07386730
Jennifer MitchellAnhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Start: 2026-06-01End: 2030-02-01Target: 80Updated: 2026-09-09
The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.
Not yet recruitingNCT07433452
Gabriella GobbiHealthy Participants, Placebo - Control, Psilocybin
Start: 2026-09-01End: 2029-09-01Target: 50Updated: 2026-02-25

Phase 2

Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
RecruitingNCT06969170
Claudio N SoaresGeneralized Anxiety Disorder (GAD)
Start: 2025-05-16End: 2028-12-30Target: 50Updated: 2026-08-12
Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression
RecruitingNCT07183748
Beersheva Mental Health CenterTreatment Resistant Depression
Start: 2025-12-01End: 2028-06-01Target: 20Updated: 2025-11-19
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
Not yet recruitingNCT07227909
M.D. Anderson Cancer CenterNeuropathy, Psilocybin
Start: 2026-11-04End: 2031-01-31Target: 83Updated: 2026-08-31
Group PACBT for Depression
Not yet recruitingNCT07566104
University of California, Los AngelesCognitive Behavioral Therapy, Depression - Major Depressive Disorder, Psilocybin
Start: 2027-01-01End: 2028-12-01Target: 30Updated: 2026-05-04
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
RecruitingNCT07610369
Yale UniversityDepression, Parkinson's Disease (PD)
Start: 2026-07-01End: 2030-07-01Target: 40Updated: 2026-07-20
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
Not yet recruitingNCT07745569
University of New MexicoMajor Depression, PTSD, PTSD - Post Traumatic Stress Disorder +1
Start: 2026-08-31End: 2030-06-30Target: 150Updated: 2026-08-04

Related Papers

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
2010-09-06743 citations